ObsEva (NASDAQ:OBSV) Now Covered by StockNews.com

StockNews.com began coverage on shares of ObsEva (NASDAQ:OBSV) in a research note published on Saturday. The firm issued a hold rating on the stock.

ObsEva Price Performance

Shares of NASDAQ OBSV opened at $0.00 on Friday. ObsEva has a one year low of $0.08 and a one year high of $2.14. The business’s 50-day moving average price is $0.02 and its two-hundred day moving average price is $0.04. The company has a market capitalization of $155,942.00, a P/E ratio of 0.00 and a beta of 0.68.

Hedge Funds Weigh In On ObsEva

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Virtu Financial LLC acquired a new position in shares of ObsEva during the 1st quarter worth $30,000. XTX Topco Ltd boosted its holdings in ObsEva by 33.9% in the first quarter. XTX Topco Ltd now owns 79,757 shares of the company’s stock worth $120,000 after purchasing an additional 20,196 shares in the last quarter. Millennium Management LLC acquired a new position in ObsEva during the second quarter worth $192,000. Credit Suisse AG raised its holdings in ObsEva by 8.7% during the third quarter. Credit Suisse AG now owns 1,577,118 shares of the company’s stock valued at $224,000 after buying an additional 126,812 shares in the last quarter. Finally, Two Sigma Investments LP acquired a new stake in shares of ObsEva in the third quarter worth about $25,000. Institutional investors own 17.52% of the company’s stock.

ObsEva Company Profile

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women’s reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.